Scholars Central

Conference abstract

End of the blockbuster model-What next?

Authors: Sreedhar D, Udupa N

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Blockbuster model is adopted by many big pharmaceutical companies where they spent large amounts of money in research and development to find a blockbuster drug. A drug is said to be blockbuster when its annual sales crosses US$ 1 Billion. The first blockbuster drug was born when Zantac surpassed US$ 1 Billion. Many blockbuster drugs came after Zantac. Over a period of time many pharmaceutical companies grew in size and have been built around these blockbuster drugs. However, blockbuster model approach is hardly followed by any company. The reasons for failure of Blockbuster model are many, to name few are declining research and development productivity, rising costs of commercialization, increasing payer influence, diminishing exclusivity period. Pharmaceutical companies focus is slowly, but steadily shifting from blockbuster model to an integrated model that brings together planned experimentation, aggressive use of partnerships where risks and benefits are shared. However, pharmaceutical companies have to think beyond blockbuster and integrated models. They need to look for incremental innovations of already existing drugs, niche segments which may include the drugs to treat a few orphan diseases, fixed-dose combinations, personalized medicines etc., Global pharmaceutical industry has become very competitive and companies have to strive very hard to just retain their previous years ranking. And, if any pharmaceutical company aims to move up the ladder, then it needs to really gear up and adapt quickly to the changing business models.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmacovigilance.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacovigilance
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Sreedhar D”
  • BylineArticles whose byline prints “Udupa N”